日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

INBRX-109(一种第三代重组人源化死亡受体5激动剂抗体)在软骨肉瘤中的临床前表征和I期试验结果

Vivek Subbiah ,Sant P Chawla ,Anthony P Conley ,Breelyn A Wilky ,Anthony Tolcher ,Nehal J Lakhani ,David Berz ,Vasily Andrianov ,William Crago ,Monica Holcomb ,Abrahim Hussain ,Carson Veldstra ,James Kalabus ,Brianne O'Neill ,Lane Senne ,Emily Rowell ,Analeah B Heidt ,Katelyn M Willis ,Brendan P Eckelman